Respiratory Syncytial Virus Clinical Trial
Official title:
Characterization of the Immune Response and Viral Shedding to Experimental Infection With Respiratory Syncytial Virus, Strain A-2, in Healthy Adults Ages 21 to 40 Years Old
The purpose of this study is to measure the immune response (how the body fights infection) to an experimental preparation of live Respiratory Syncytial Virus (RSV). A better understanding of this virus may be useful in development of vaccines and treatments. Participants will include 20 healthy adults age 21-40. Study procedures will include drawing blood, urine samples, respiratory exams, vital signs and temperature, diary cards, nasal mucus weight and nasal washes and swabs. All participants will receive vaccine via nose drops. Patients will participate in the study for about 2 months.
Status | Completed |
Enrollment | 13 |
Est. completion date | May 2005 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 21 Years to 40 Years |
Eligibility |
Inclusion Criteria: Healthy adults ages 21 to 40 years. Able to and has given informed consent to participate. Negative urine pregnancy test, if female. Pre-challenge serum neutralizing titer to RSV A2 by microneutalization (MNA) of </= 1:657 (9.36 log2) Non-smoker No significant health abnormalities detected by evaluation of medical history, general physical examination, vital signs and laboratory tests. Willingness to remain in isolation for 11 nights and comply with all study requirements. Willingness to remain in the Rochester area for the 28 days of the study. Exclusion Criteria: Volunteers with any of the following conditions will not be eligible to participate: Chronic medical conditions requiring medical followup within the last 6 months. Serologic evidence of infection with HIV or hepatitis C virus, or presence of hepatitis B surface antigen in serum. History of medically documented asthma requiring treatment (including over-the-counter medications) at any time. Any abnormal laboratory results which would render challenge with RSV unsafe or interfere with the interpretation of the subject's response to challenge, e.g., AST, ALT, Bilirubin, BUN, creatinine. ( see Appendix II) Individuals requiring concurrent therapy with medications likely to interfere with evaluation of the response to infection, e.g. antipyretics, anti-inflammatory medications Close contact with children aged less than 2 years, with any individuals with significant immunosuppression, or with individuals greater than 65 years of age. Health care workers with any patient contact during the two weeks following challenge Pregnancy or uncertain status regarding pregnancy Acute respiratory infection or fever within 1 week of challenge Previous enrollment in a study evaluating RSV challenge viruses or RSV vaccines. Known glucose intolerance (history of abnormal glucose tolerance test or medical history of diabetes mellitus). History of chronic obstructive disease, emphysema or other serious or evolving pulmonary disease. Any condition in the opinion of the investigator might interfere with study objectives or pose excessive risks to subjects. History of previous hospitalization for a pulmonary condition (ie. Pneumonia, asthma, spontaneous pneumothorax, or severe sinus disease requiring a surgical procedure. History of frequent serious bacterial infections associated with low white blood cell count (below 4,000 per microgram) |
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
Country | Name | City | State |
---|---|---|---|
United States | Rochester General Hospital | Rochester | New York |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04528719 -
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive
|
Phase 1 | |
Terminated |
NCT02508194 -
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
|
Phase 2 | |
Active, not recruiting |
NCT06060457 -
A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age
|
Phase 3 | |
Terminated |
NCT01757496 -
Cough Assist in Bronchiolitis
|
N/A | |
Completed |
NCT03524118 -
Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05572658 -
Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study
|
||
Recruiting |
NCT06067230 -
A Study to Investigate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults
|
Phase 3 | |
Completed |
NCT00246480 -
RSV Disease in the Elderly
|
||
Active, not recruiting |
NCT06097299 -
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus
|
Phase 2 | |
Completed |
NCT00889070 -
Respiratory Events Among Premature Infants
|
N/A | |
Unknown status |
NCT00613184 -
Comparison of Nylon Flocked Swabs and Saline Aspirates for Detection Respiratory Viruses
|
N/A | |
Completed |
NCT05559905 -
Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017)
|
Phase 2 | |
Active, not recruiting |
NCT05127434 -
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
|
Phase 2/Phase 3 | |
Terminated |
NCT04978337 -
A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection
|
Phase 2 | |
Recruiting |
NCT06143046 -
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers
|
Phase 2 | |
Active, not recruiting |
NCT05397223 -
A Study of Modified mRNA Vaccines in Healthy Adults
|
Phase 1 | |
Completed |
NCT02472548 -
A Study to Evaluate the Safety and Reactogenicity of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine
|
Phase 1 | |
Completed |
NCT01562938 -
MEDI-557 Adult Dosing
|
Phase 1 | |
Completed |
NCT01734668 -
Sofia RSV FIA Field Study
|
N/A | |
Recruiting |
NCT06325657 -
A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants
|
Phase 3 |